Sanofi's Executive leadership reshuffle: the key changes. July 23, 2026 Sanofi's revamped executive team brings leaders from across the company's key global functions to support its "next strategic chapter" and future growth Sanofi has announced a reshaped Executive Committee and key leadership changes as the pharmaceutical giant prepares for its next phase of growth, bringing together a streamlined executive team from across its commercial businesses, research organisations and global functions. Belén Garijo, CEO at Sanofi, says the refreshed leadership team will help guide the company through its next stage of development while maintaining a strong focus on patients and innovation. "This Executive Committee brings together experienced professionals who will work together to help shape our future direction, make disciplined choices, execute them with focus and ensure we continue to deliver for our patients, our people and all our stakeholders," she says. A new chapter. As of 1 September 2026, Sanofi's Executive Committee will comprise: * Paulo Fontoura, Executive Vice President, Head of Research & Development (Formerly Chief Medical Officer at Xaira Therapeutics) * Thomas Grenier, Executive Vice President, General Medicines (Formerly Head of North America, Vaccines) * François Roger, Executive Vice President, Finance (Formerly Chief Financial Officer) * Jamie Haney, Executive Vice President, General Counsel (Formerly Senior Vice President - General Counsel North America & Global Specialty Care) * Véronique Jaillet, Executive Vice President, Interim Chief People Officer (Formerly Head of Global Human Resources Manufacturing & Supply) * Manuela Buxo, Executive Vice President, Specialty Care * Thomas Triomphe, Executive Vice President, Vaccines * Brendan O'Callaghan, Executive Vice President, Manufacturing & Supply Paulo Fontoura is a new hire who will join Sanofi on 1 September 2026 from AI-focused biotechnology company Xaira Therapeutics, where he served as Chief Medical Officer. Discussing his new role on LinkedIn, Paulo writes, "I am incredibly excited to be joining Belén Garijo and everyone at team Sanofi in this new role, to work together to create an amazing pipeline of new medicines that will make a real difference in the lives of patients. "I am convinced that we stand at the threshold of a revolution in biopharma R&D, where we can combine our deepening understanding of disease biology with new computational tools in AI/ML to derive new insights that will solve the most complex biology problems and create cures for many more diseases around the world." New responsibilities for key executives. In addition to the refreshed Executive Committee, Sanofi announced that several key figures in its leadership team have taken on new responsibilities as part of the reshuffle. Thomas Triomphe will add responsibility for China alongside his existing role as Executive Vice President of Vaccines, while Olivier Charmeil will step down as Executive Vice President of General Medicines to become Strategic Projects Advisor to CEO Belén Garijo. Madeleine Roach will become President and Country Lead for Germany, Switzerland and Austria, with her Business Operations responsibilities being absorbed into Sanofi's Finance division under François Roger. The expanded finance function will also take responsibility for Global Partnering and Business Development, bringing business development and mergers and acquisitions activities under a single leadership structure. The company says the move is intended to create a more integrated approach to identifying and executing strategic growth opportunities. Maintaining 2026's momentum. The leadership changes follow a busy first half of 2026 for Sanofi, marked by a series of regulatory milestones and pipeline advances. In June, the European Commission approved Sanofi's Cenrifki medication as the first disability-targeting treatment for secondary progressive multiple sclerosis without relapses, while the company also secured US approval for Tzield as the first disease-modifying therapy for recently diagnosed stage 3 type 1 diabetes. Sanofi has also made strong progress in strengthening its rare disease portfolio in 2026 after receiving US approval for an on-body injector version of its multiple myeloma therapy Sarclisa Escena and reporting positive Phase III results for Nexviazyme in infantile-onset Pompe disease. Executives. * Belén Garijo CEO * Brendan O'Callaghan Executive Vice President, Manufacturing and Supply * François-Xavier Roger Executive Vice President, Finance * Jamie Haney Executive Vice President, General Counsel * Madeleine Roach President and Country Lead for Germany, Switzerland and Austria * Manuela Buxo Executive Vice President, Specialty Care * Olivier Charmeil Strategic Projects Advisor * Paulo Fontoura Global Head of Research & Development Pharma * Thomas Triomphe Executive Vice President Vaccines, Sanofi * Veronique Jaillet Head of Global Human Resources Manufacturing & Supply, Sanofi Company Portals

Xaira Therapeutics expands leadership team with executive appointment and internal promotions. July 6, 2026 Xaira Therapeutics has strengthened its executive leadership team with the appointment of Ian McCaffery, Ph.D., as Senior Vice President of Translational Science and Early Clinical Development, while promoting Ci Chu, Ph.D., to Chief Discovery Officer and Bo Wang, Ph.D., to Chief AI Scientist. The South San Francisco-based biotechnology company said all three executives will report to CEO Marc Tessier-Lavigne as it advances its AI-driven drug discovery and development platform. The leadership changes come as Xaira continues to expand the operational capabilities behind its artificial intelligence models and therapeutic pipeline. McCaffery will oversee the company's precision medicine strategy, translational science efforts and early clinical development programs, with responsibility for advancing AI-designed therapeutics into clinical studies. His role also includes guiding Xaira's patient stratification initiatives through the company's AI-driven disease analysis platform while working closely with Chu and Wang to develop models that improve understanding of disease variation and patient responses. McCaffery joins Xaira from AbbVie, where he served as Vice President and Global Head of Precision Medicine and Companion Diagnostics. During his tenure, he led multidisciplinary teams spanning translational science, clinical development, diagnostics and engineering across oncology, immunology and neuroscience programs. His work incorporated clinical data, real-world evidence and artificial intelligence to support drug development, target identification and regulatory submissions, including investigational new drug applications, biologics license applications, new drug applications and companion diagnostic approvals. CEO Marc Tessier-Lavigne said McCaffery's experience across translational research, precision medicine, diagnostics and AI-enabled discovery positions him to help advance the company's X-Patient platform alongside its growing clinical development portfolio. He added that Chu and Wang have played central roles in building Xaira's biology and AI capabilities, and their promotions reflect both their contributions and the company's next phase of growth. McCaffery said advances in computational capabilities combined with expanding biological datasets have created an opportunity to reshape how medicines are discovered and developed, adding that Xaira is well positioned to capitalize on that convergence. The internal promotions recognize two scientists who have helped establish the company's AI-enabled research infrastructure since its launch. Chu, previously Senior Vice President of AI-Enabled Discovery, has led Xaira's high-throughput biology organization, generating large-scale experimental datasets used to train the company's virtual cell models and support therapeutic design. Before joining Xaira, she led high-content phenotyping and functional genomics teams at insitro, bringing experience at the intersection of automated biology and machine learning. As Chief AI Scientist, Wang will continue leading the company's biomedical AI strategy. A former associate professor at the University of Toronto, he has focused his research on foundation models for healthcare and biology, including AI systems for genomic analysis, biomolecular modeling and precision medicine. He also led development of scGPT, described as the first single-cell foundation model, and BioReason, a biological reasoning model. Together, Chu and Wang have helped develop X-Cell, Xaira's first virtual cell model, along with the X-Atlas/Pisces dataset that underpins it. According to the company, X-Cell was trained using what it describes as the largest publicly released genome-wide CRISPRi Perturb-seq dataset, consisting of 25.6 million perturbed single-cell transcriptomes across seven biologically distinct cellular contexts. The 4.9-billion-parameter model is designed to predict cellular responses to genetic perturbations and support AI-guided therapeutic discovery. Chu said the effectiveness of AI in drug discovery depends heavily on the quality and scale of biological data, noting that Xaira's integrated laboratory and computational workflows are intended to create a continuous feedback loop between experimental research and machine learning models. Wang added that the company's goal is to ensure AI produces measurable scientific advances, describing X-Cell as an example of applying large-scale models to improve biological research and therapeutic development. Founded to integrate machine learning, large-scale biological data generation and drug development into a unified platform, Xaira Therapeutics is building a pipeline of AI-designed medicines that the company said is progressing toward clinical development. In addition to its headquarters in South San Francisco, the company operates innovation centers in Seattle and London.

Xaira Therapeutics has appointed Rachel Lane as Senior Vice President of Business Development and Operations. She will oversee business development strategy and drive partnerships integrating machine learning with therapeutic development. Lane brings over a decade of biotech leadership experience as an operator and investor. Most recently, she served as Chief Business Officer at Belharra Therapeutics, where she closed major platform partnerships with Genentech and Sanofi. She previously worked at Versant Ventures and holds a PhD in Molecular Genetics and Cell Biology. This month, Xaira launched X-Cell, its virtual cell model trained on 25.6 million perturbed single-cell transcriptomes. The 4.9 billion-parameter model predicts outcomes of genetic perturbations, marking progress towards transforming drug discovery into a predictive engineering discipline.